As capital comes back home to the U.S., we are seeing President Trump’s tax reform pay off bigly for our country.
U.S.-based Pfizer this week announced that it will combine its off-patent drug business with Dutch company Mylan and form a new U.S.-based company.
And Illinois-headquartered AbbVie recently announced it would acquire the Irish company Allergan PLC.
These are both fresh new demonstrations that President Trump’s tax reform enacted at the end of 2017 is clearly doing what it was intended to do – making the U.S. more competitive.